AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $293.45 billion. The enterprise value is $318.47 billion.
Important Dates
The next confirmed earnings date is Tuesday, February 10, 2026, before market open.
| Earnings Date | Feb 10, 2026 |
| Ex-Dividend Date | Aug 7, 2025 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has decreased by -0.08% in one year.
| Current Share Class | 1.55B |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 80.51% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 31.33 and the forward PE ratio is 38.21.
| PE Ratio | 31.33 |
| Forward PE | 38.21 |
| PS Ratio | 5.05 |
| Forward PS | 4.67 |
| PB Ratio | 6.38 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 23.18 |
| P/OCF Ratio | 19.38 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 15.60, with an EV/FCF ratio of 25.16.
| EV / Earnings | 33.88 |
| EV / Sales | 5.48 |
| EV / EBITDA | 15.60 |
| EV / EBIT | 20.02 |
| EV / FCF | 25.16 |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.71.
| Current Ratio | 0.88 |
| Quick Ratio | 0.69 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 1.57 |
| Debt / FCF | 2.58 |
| Interest Coverage | 12.24 |
Financial Efficiency
Return on equity (ROE) is 21.67% and return on invested capital (ROIC) is 18.54%.
| Return on Equity (ROE) | 21.67% |
| Return on Assets (ROA) | 9.06% |
| Return on Invested Capital (ROIC) | 18.54% |
| Return on Capital Employed (ROCE) | 19.78% |
| Weighted Average Cost of Capital (WACC) | 5.10% |
| Revenue Per Employee | $625,694 |
| Profits Per Employee | $101,173 |
| Employee Count | 92,900 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.59 |
Taxes
In the past 12 months, AstraZeneca has paid $2.04 billion in taxes.
| Income Tax | 2.04B |
| Effective Tax Rate | 17.79% |
Stock Price Statistics
The stock price has increased by +33.50% in the last 52 weeks. The beta is 0.19, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | +33.50% |
| 50-Day Moving Average | 183.44 |
| 200-Day Moving Average | 158.45 |
| Relative Strength Index (RSI) | 55.00 |
| Average Volume (20 Days) | 358,351 |
Short Selling Information
The latest short interest is 12.27 million, so 0.79% of the outstanding shares have been sold short.
| Short Interest | 12.27M |
| Short Previous Month | 8.32M |
| Short % of Shares Out | 0.79% |
| Short % of Float | 0.79% |
| Short Ratio (days to cover) | 2.25 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $58.13 billion and earned $9.40 billion in profits. Earnings per share was $6.02.
| Revenue | 58.13B |
| Gross Profit | 48.40B |
| Operating Income | 15.91B |
| Pretax Income | 11.44B |
| Net Income | 9.40B |
| EBITDA | 20.42B |
| EBIT | 15.91B |
| Earnings Per Share (EPS) | $6.02 |
Full Income StatementBalance Sheet
The company has $8.18 billion in cash and $32.66 billion in debt, with a net cash position of -$24.48 billion or -$15.78 per share.
| Cash & Cash Equivalents | 8.18B |
| Total Debt | 32.66B |
| Net Cash | -24.48B |
| Net Cash Per Share | -$15.78 |
| Equity (Book Value) | 45.97B |
| Book Value Per Share | 29.59 |
| Working Capital | -4.11B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $15.14 billion and capital expenditures -$2.48 billion, giving a free cash flow of $12.66 billion.
| Operating Cash Flow | 15.14B |
| Capital Expenditures | -2.48B |
| Free Cash Flow | 12.66B |
| FCF Per Share | $8.16 |
Full Cash Flow StatementMargins
Gross margin is 83.26%, with operating and profit margins of 27.37% and 16.17%.
| Gross Margin | 83.26% |
| Operating Margin | 27.37% |
| Pretax Margin | 19.68% |
| Profit Margin | 16.17% |
| EBITDA Margin | 35.12% |
| EBIT Margin | 27.37% |
| FCF Margin | 21.78% |
Dividends & Yields
This stock pays an annual dividend of $3.13, which amounts to a dividend yield of 1.66%.
| Dividend Per Share | $3.13 |
| Dividend Yield | 1.66% |
| Dividend Growth (YoY) | 213.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 52.00% |
| Buyback Yield | 0.08% |
| Shareholder Yield | 1.78% |
| Earnings Yield | 3.20% |
| FCF Yield | 4.31% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 7.74% |
| EPS Growth Forecast (5Y) | 11.04% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 2.98 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.98 |
| Piotroski F-Score | 7 |
